{"id":11849,"date":"2020-01-20T10:33:02","date_gmt":"2020-01-20T09:33:02","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=11849"},"modified":"2020-01-27T10:19:17","modified_gmt":"2020-01-27T09:19:17","slug":"estudi-pensa-una-aposta-per-la-prevencio-primaria-en-lalzheimer","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/estudi-pensa-una-aposta-per-la-prevencio-primaria-en-lalzheimer\/","title":{"rendered":"Estudi PENSA: una aposta per la prevenci\u00f3 prim\u00e0ria en l&#8217;Alzheimer"},"content":{"rendered":"<p>Es preveu\u00a0que,\u00a0<a href=\"https:\/\/www.theguardian.com\/world\/2018\/oct\/16\/spain-to-beat-japan-2040-world-life-expectancy-league-table\">per l\u2019any 2040, Espanya lideri el llistat de pa\u00efsos amb major esperan\u00e7a de vida<\/a>. Per\u00f2 aquest augment en l\u2019esperan\u00e7a de vida es relaciona, entre d\u2019altres, amb un increment en la xifra d\u2019individus afectats per malalties neurodegeneratives, com \u00e9s el cas de l\u2019Alzheimer. Actualment es calcula que,\u00a0<strong><a href=\"https:\/\/www.imim.es\/media\/upload\/pdf\/np_estudi_alzheimer_v7-2_castdef_editora_17_721_1.pdf\">a Espanya, el nombre de persones que pateixen dem\u00e8ncia \u00e9s de 800.000<\/a><\/strong>, xifra que podria\u00a0<strong>multiplicar-se per tres de cara al 2050<\/strong>, arribant a dimensions d\u2019<strong>epid\u00e8mia<\/strong>.<\/p>\n<p>Amb l&#8217;objectiu de comprovar si \u00e9s possible <strong>aturar el declivi cognitiu en estadis previs a l&#8217;aparici\u00f3 de la dem\u00e8ncia<\/strong>, investigadors de l&#8217;<a href=\"http:\/\/www.imim.es\/\" target=\"_blank\" rel=\"noopener\">Institut Hospital del Mar d\u2019Investigacions M\u00e8diques\u00a0(IMIM)<\/a>, liderats per <strong>Rafael de la Torre<\/strong>, i del\u00a0<a href=\"https:\/\/www.barcelonabeta.org\/ca\" target=\"_blank\" rel=\"noopener\">Barcelona Beta Brain Research Center (BBRC)<\/a>\u00a0han impulsat l&#8217;<strong><a href=\"https:\/\/www.pensaalzheimer.org\/ca\/\" target=\"_blank\" rel=\"noopener\">Estudi PENSA<\/a> <\/strong>(<em>Prevention of cognitive decline in ApoE4 carriers with Subjective Cognitive Decline after EGCG and a multimodal intervention<\/em>). Actualment, l&#8217;estudi es troba en fase de <a href=\"https:\/\/www.pensaalzheimer.org\/ca\/inscripcio\" target=\"_blank\" rel=\"noopener\"><strong>reclutament de participants<\/strong><\/a>, els quals han de complir les seg\u00fcents caracter\u00edstiques:<\/p>\n<ul>\n<li>Tenir entre <strong>60 i 80 anys<\/strong>.<\/li>\n<li>Estar en <strong>bon estat f\u00edsic<\/strong> per poder realitzar les proves.<\/li>\n<li>Percebre <strong>certs problemes de mem\u00f2ria<\/strong> que anteriorment no notaven.<\/li>\n<li>Preferiblement, <strong>viure a Barcelona<\/strong> per tal de poder assistir a les visites presencials programades en l&#8217;estudi.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><iframe loading=\"lazy\" width=\"1170\" height=\"658\" src=\"https:\/\/www.youtube.com\/embed\/oM7M6doRODQ?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>&nbsp;<\/p>\n<p>Els <strong>200 individus seleccionats<\/strong> se sotmetran a un <strong>assaig cl\u00ednic de prevenci\u00f3<\/strong> durant tot un any, que consistir\u00e0 en:<\/p>\n<ul>\n<li>per un costat, un\u00a0<strong>canvi en els h\u00e0bits de vida<\/strong> (seguiment d&#8217;una dieta mediterr\u00e0nia, exercici f\u00edsic i entrenament cognitiu).<\/li>\n<li>per l&#8217;altre, la ingesta d&#8217;un <strong>component del te verd<\/strong> que<a href=\"https:\/\/ellipse.prbb.org\/ca\/que-el-coneixement-que-generem-millori-la-vida-de-les-persones-es-la-meva-major-satisfaccio\/\" target=\"_blank\" rel=\"noopener\"> ja ha demostrat, de manera combinada, tenir efectes positius en la funci\u00f3 cognitiva<\/a> de persones amb <a href=\"https:\/\/ellipse.prbb.org\/ca\/ciencia-i-societat-juntes-per-avancar-en-la-recerca-de-la-sindrome-de-down\/\" target=\"_blank\" rel=\"noopener\">S\u00edndrome de Down<\/a>: l&#8217;<strong>epigalocatequina galat (EGCG)<\/strong>.<\/li>\n<\/ul>\n<p>Per tal de poder estudiar l&#8217;evoluci\u00f3 dels participants, aix\u00ed com l&#8217;impacte de l&#8217;aplicaci\u00f3 del programa, <strong>el projecte PENSA ha rebut una subvenci\u00f3 d&#8217;un mili\u00f3 de d\u00f2lars<\/strong> de l&#8217;<a href=\"https:\/\/www.alz.org\/\" target=\"_blank\" rel=\"noopener\">Alzheimer&#8217;s Association<\/a> dels EEUU, i s&#8217;emmarca dins del projecte mundial de prevenci\u00f3 prim\u00e0ria <a href=\"https:\/\/www.alz.org\/wwfingers\/overview.asp\" target=\"_blank\" rel=\"noopener\">World Wide FINGERS<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<blockquote><p>\u00abLa gran aposta en l&#8217;Alzheimer \u00e9s la prevenci\u00f3 prim\u00e0ria, \u00e9s a dir, evitar que les persones arribin a necessitar un tractament. Amb l&#8217;estudi PENSA volem aconseguir precisament aix\u00f2, frenar la progressi\u00f3 del declivi cognitiu cap a una futura malaltia neurodegenerativa\u00bb<br \/>\n<strong>Rafael de la Torre (IMIM)<\/strong><\/p><\/blockquote>\n<p>&nbsp;<\/p>\n<p>Hem parlat amb l&#8217;investigador de l&#8217;IMIM i coordinador de l&#8217;Estudi PENSA, Rafael de la Torre. En el seg\u00fcent video ens explica la import\u00e0ncia de participar en aquesta prova pilot.<\/p>\n<p>&nbsp;<\/p>\n<p><iframe loading=\"lazy\" width=\"1170\" height=\"658\" src=\"https:\/\/www.youtube.com\/embed\/aquP4VWNRR4?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Investigadors de l&#8217;IMIM cerquen persones amb problemes de mem\u00f2ria per participar en un assaig cl\u00ednic de prevenci\u00f3 de la dem\u00e8ncia. Els participants han de tenir entre 60 i 80 anys.<\/p>\n","protected":false},"author":9,"featured_media":12220,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[320,651,213,663],"new-type":[35],"class_list":["post-11849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-alzheimer","tag-assaigs-clinics","tag-imim","tag-prevencio","new-type-noticies"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/11849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=11849"}],"version-history":[{"count":5,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/11849\/revisions"}],"predecessor-version":[{"id":12399,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/11849\/revisions\/12399"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/12220"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=11849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=11849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=11849"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=11849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}